Get the Stockscreener App
5.21
2.96%
0.15
After Hours:
4.98
-0.23
-4.41%
Rezolute Inc stock is traded at $5.21, with a volume of 333.06K.
It is up +2.96% in the last 24 hours and up +6.54% over the past month.
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
See More
Previous Close:
$5.06
Open:
$5.1
24h Volume:
333.06K
Relative Volume:
0.76
Market Cap:
$301.88M
Revenue:
-
Net Income/Loss:
$-68.46M
P/E Ratio:
-3.9173
EPS:
-1.33
Net Cash Flow:
$-57.37M
1W Performance:
+4.41%
1M Performance:
+6.54%
6M Performance:
+15.78%
1Y Performance:
+345.30%
1-Day Range:
$4.93
$5.23
1-Week Range:
$4.40
$5.23
52-Week Range:
$0.9199
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
5.21 | 301.88M | 0 | -68.46M | -57.37M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Rezolute receives breakthrough therapy designation for treatment of hypoglycemia - MSN
Cantor Fitzgerald Predicts Rezolute FY2025 Earnings - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat
Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa
Rezolute shares Phase 2 clinical study update - Investing.com
Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks
(RZLT) On The My Stocks Page - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance
FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan
State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat
Rezolute CFO Daron Evans buys $42,900 in company stock By Investing.com - Investing.com Australia
Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com India
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com Nigeria
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential By Investing.com - Investing.com South Africa
Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St
Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Comparison - Defense World
When the Price of (RZLT) Talks, People Listen - Stock Traders Daily
Rezolute expands authorized shares following shareholder approval - Investing.com
Daron Evans, CFO of Rezolute, buys $53,166 in common shares By Investing.com - Investing.com Nigeria
Daron Evans, CFO of Rezolute, buys $53,166 in common shares - Investing.com
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug - MSN
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rezolute Grants 150,000-Share Inducement Award to New Supply Chain Executive - StockTitan
Rezolute retains steady stock target on Orphan Drug nod By Investing.com - Investing.com Canada
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - Marketscreener.com
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market (NASDAQ:RZLT) - Seeking Alpha
Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment - MarketWatch
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
Rezolute's Hypoglycemia Drug Wins FDA Orphan Drug Status; Phase 3 Trial Set for 2025 - StockTitan
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts - MarketBeat
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies - TipRanks
BTIG Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - MSN
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2024 - Marketscreener.com
Wedbush Initiates Coverage of Rezolute (RZLT) with Outperform Recommendation - MSN
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):